AURORA, ON--(Marketwired - Apr 1, 2015) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announced on March 16, 2015 that the Company received subscription agreements totaling a net aggregate of CAD$5.2 million. The Company today announced that this first private placement has now closed and that it has received additional private placement subscription agreements for common shares and warrants for aggregate net proceeds of approximately CAD$3.9 million after expected expenses.
Upon closing of both the first and second private placements, the net proceeds from this round of financing will total CAD$9.1 million after expected expenses.
The terms of the second private placement financing, which are the same as those offered in the first, are for the purchase of common shares at CAD$1.10 per share and include one warrant per share at an exercise price of CAD$1.54 and have an expiry of five years from the date of issue.
“We would like to thank both our existing shareholders and the new investors who participated in these private placements for the Company,” stated Robert Verhagen, President & CEO of Helix. “We are committed to moving forward with the development of L-DOS47 in Poland and the US, to explore new opportunities with the DOS47 platform and other growth opportunities that can build value in Helix.”
ACM Alpha Consulting Management Est. provided financial advisory services to Helix in connection with the private placements. The closing of the second private placement is subject to approval by the Toronto Stock Exchange.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
Help employers find you! Check out all the jobs and post your resume.